Virios Therapeutics (VIRI) Stock Price, News & Analysis

Company Overview

Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.

The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids. In addition, Virios is advancing VTI-105, which is being evaluated for its potential to promote wound healing in patients with diabetic foot ulcers. These programs reflect Virios’s broader strategy of addressing both dermatological and systemic fibrotic indications through targeted inhibition of pro-fibrotic signaling cascades.

Headquartered in St. Louis, Missouri, Virios operates research and development activities in the United States. Since going public on the Nasdaq exchange under the ticker VIRI, the company has collaborated with academic institutions and contract research organizations to support its preclinical and clinical studies. Virios’s leadership team is spearheaded by Chief Executive Officer Sumita Roy, Ph.D., whose experience in drug discovery and translational research guides the company’s scientific and strategic direction.

As a specialty biopharma enterprise, Virios Therapeutics is committed to advancing innovative therapies from early-stage research through regulatory approval. By focusing on diseases characterized by excessive scarring and impaired healing, the company seeks to bring novel treatment modalities to patients and create long-term value for stakeholders.

Key Stats

• Today's Range: $1.41 to $1.47
• 50-Day Range: $1.34 to $3.22
• 52-Week Range: $0.13 to $1.04
• Volume: 44,057 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $27.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VIRI Stock Analysis - Frequently Asked Questions

How have VIRI shares performed this year?

Virios Therapeutics' stock was trading at $4.16 on January 1st, 2026. Since then, VIRI stock has decreased by 65.4% and is now trading at $1.44.

How were Virios Therapeutics' earnings last quarter?

Virios Therapeutics, Inc. (NASDAQ:VIRI) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02.

When did Virios Therapeutics IPO?

Virios Therapeutics (VIRI) raised $30 million in an IPO on Thursday, December 17th 2020. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

How do I buy shares of Virios Therapeutics?

Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Virios Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Virios Therapeutics investors own include Meta Platforms (META), AMC Entertainment (AMC), SNDL (SNDL), CISO Global (CISO), Canoo (GOEV), Organigram Global (OGI).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIRI
• CIK: 1818844
• Web: www.virios.com
• Phone: 866-620-8655
• Fax: N/A
• Employees: 5
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -130.33%
• Return on Assets: -115.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.27
• Quick Ratio: 7.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 7.20

Miscellaneous

• Outstanding Shares: 19,258,000
• Free Float: 16,909,000
• Market Cap: $27.73 million
• Optionable: No Data
• Beta: 1.58